Non Alcoholic Fatty Liver Disease
Conditions
Keywords
Hepatic insulin sensitivity, Muscle insulin sensitivity, B cell function, VLDL1 TG metabolism, VLDL2 TG metabolism
Brief summary
This project examines the effects of a 4 month structured exercise intervention program in patients with non-alcoholic fatty liver disease (NAFLD). We will examine changes in total and depot-specific (i.e.in different tissues, liver, muscle and pancreas)fat. We will correlate these with measurements of the insulin from the liver. The hypothesis is that by reducing fat in these specific depots we can reduce insulin resistance and prevent progression to diabetes.
Detailed description
1. Exercise program: We are asking people to take part in a supervised exercise program for 4 months. This involves on average a weekly supervised exercise bout plus other unsupervised exercise bouts at home. We will ensure participants are physically able to embark on this by taking their medical history, physical examination and validated questionnaire (PARQ). This program is for the benefit on the patients' long term health. 2. MR imaging to assess fat: occassionally these may pick up anomalies which require further investigation. A radiologist will screen the abdominal images and GP will be informed on anything requiring further investigation. No radiation is received during MR imaging. 3. Physiological studies: Patients will be asked to attend for 2 non-consecutive days before and after the exercise intervention. Regular blood samples will be required as apart of these investigations.
Interventions
BEHAVIORALUnsupervised exercise training
The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
BEHAVIORALSupervised exercise training
Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
Sponsors
Royal Liverpool University Hospital
University of Surrey
Imperial College London
Royal Surrey County Hospital NHS Foundation Trust
University of Liverpool
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Sedentary, non smoking, male subjects, * Alcohol consumption men \<21 units/week, * BMI 27-35. (Lean individuals do not suffer from NAFLD, so are not suitable for this study. Conversely, we are restricted to a maximum BMI of 35 due to the size limitations of the MR scanner.) * A clinical diagnosis of NAFLD based upon the following criteria: i) exclusion of other causes of liver disease i.e. negative Hepatitis B and C serology, a negative auto-immune profile and normal caeruloplasmin concentrations, ii) Ultrasound appearances suggestive of a fatty, echo-bright liver with no evidence of cirrhosis (in some cases, the diagnosis will have been confirmed histologically after liver biopsy. * Being willing to engage and motivated to follow an exercise program.
Exclusion criteria
* Prescription of corticosteroids, amiodarone, tamoxifen, methotrexate (drugs known to cause secondary steatohepatitis) or fibrates. Statin is Ok as long as the patients are on stable therapy for a while, if changed then the patient will be excluded. * Alcohol consumption for men 21 units/week. * A contraindication to exercise (such as unstable ischaemic heart disease), * Type 2 diabetes (type 2 diabetes patients are excluded so that we are examining the involvement of insulin resistance at a reversible stage before β-cell failure has occurred). * Patients who are on medications that will interact with GTN (glyceryl trinitrate) will be excluded from the GTN dilatation (endothelial independent NO mediated function) aspect of the study. * Individuals who suffer from claustrophobia and have metal implants will be excluded from the MRI aspect of the study. * Patients who smoke will also be excluded from the study. * Total cholesterol \>7
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in liver and muscle fat | 4 months | Tissue triglyceride content, or steatosis, will be accurately and non-invasively quantified in vivo using localized proton magnetic resonance spectroscopy (1H MRS). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in liver function tests | 4 months | Biochemial measurements of the liver enzymes will be measured pre and post intervention period |
| Changes in lipid profiles | 4 months | Total cholesterol, triglyceride and high density lipoprotien concentrations in fasting state will be measured pre and post intervention period. |
| Changes in body weight and anthropometric measurements | 4 months | Body weight and waist to hip ratio will be measured pre and post intervention period. |
| Hepatic insulin sensitivity | 4 months | Half of the study cohort i.e. 30 individuals,15 exercise and 15 controls, will have peripheral and hepatic insulin sensitivity determined using a two-stage hyperinsulinaemic, euglycaemic clamp and use of deuterated glucose (2H2-glucose |
| VLDL-TG kinetics | 4 months | The other half of the study cohort i.e. 30 individuals, 15 exercise and 15 controls, will have VLDL1 and VLDL2 TG kinetics determined using 5H2 glycerol bolus. |
Countries
United Kingdom
Outcome results
None listed